Role of Late Sodium Channel Current in Arrhythmogenesis

Cardiac Electrophysiology Clinics

Volumn 3, Issue 1, 2011, Pages 125-140

  Shryock, John C ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Angina; Arrhythmias; Heart failure; Ischemia; Late INa; Nav1.5; Sodium channel

Indexed keywords

ACONITINE; AMIODARONE; ANGIOTENSIN II; ANKYRIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALMODULIN; CARDIAC GLYCOSIDE; CAVEOLIN; FLECAINIDE; HYDROGEN PEROXIDE; ISOPRENALINE; LIDOCAINE; MEXILETINE; MIDOSTAURIN; N [1 [4 (4 FLUOROPHENOXY)BUTYL] 4 PIPERIDINYL] N METHYL 2 BENZOTHIAZOLAMINE; PHENYTOIN; PROPRANOLOL; PROTEIN KINASE FYN; QUINIDINE; RANOLAZINE; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SEA ANEMONE TOXIN; SODIUM CHANNEL; SODIUM CHANNEL NAV1.5; SYNTROPHIN; TETRODOTOXIN; UNINDEXED DRUG; VERAPAMIL; VERATRIDINE;

ARRHYTHMOGENESIS; ATRIOVENTRICULAR BLOCK; CELL MEMBRANE DEPOLARIZATION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; ISCHEMIC HEART DISEASE; PATHOLOGY; PRIORITY JOURNAL; REPOLARIZATION; REVIEW; SODIUM CALCIUM EXCHANGE;

EID: 78751629310     PISSN: 18779182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccep.2010.10.005     Document Type: Review

References (207)

1. Miyamoto S., Zhu B.M., Aye N.N., et al. Slowing Na+ channel inactivation prolongs QT interval and aggravates adrenaline-induced arrhythmias. Jpn J Pharmacol 2001, 86:114-119.
2. Maltsev V.A., Silverman N., Sabbah H.N., et al. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 2007, 9:219-227.
3. Sakmann B.F., Spindler A.J., Bryant S.M., et al. Distribution of a persistent sodium current across the ventricular wall in guinea pigs. Circ Res 2000, 87:910-914.
4. Ward C.A., Giles W.R. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol 1997, 500(Pt 3):631-642.
5. Kiyosue T., Arita M. Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. Circ Res 1989, 64:389-397.
6. January C.T., Riddle J.M. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 1989, 64:977-990.
7. Zaza A., Belardinelli L., Shryock J.C., et al. Pathophysiology and pharmacology of the cardiac " late sodium current" Pharmacol Ther 2008, 119:326-339.
8. Guo D., Zhou J., Zhao X., et al. L-type calcium current recovery versus ventricular repolarization: preserved membrane-stabilizing mechanism for different QT intervals across species. Heart Rhythm 2008, 5:271-279.
9. Viswanathan P.C., Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc Res 1999, 42:530-542.
10. Zabel M., Hohnloser S.H., Behrens S., et al. Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J Cardiovasc Electrophysiol 1997, 8:1148-1158.
11. Volders P.G., Vos M.A., Szabo B., et al. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 2000, 46:376-392.
12. Zygmunt A.C., Eddlestone G.T., Thomas G.P., et al. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 2001, 281:H689-H697.
13. Antzelevitch C., Belardinelli L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S79-S85.
14. Dos Santos R.W., Otaviano C.F., Neumann C.L., et al. ATX-II effects on the apparent location of M cells in a computational model of a human left ventricular wedge. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S86-S95.
15. Makielski J.C., Farley A.L. Na(+) current in human ventricle: implications for sodium loading and homeostasis. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S15-S20.
16. Bers D.M. Excitation-contraction coupling and cardiac contractile force 2001, Kluwer Academic Publishers, Dordrecht (The Netherlands).
17. Despa S., Islam M.A., Weber C.R., et al. Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 2002, 105:2543-2548.
18. Maier L.S., Hasenfuss G. Role of [Na+]i and the emerging involvement of the late sodium current in the pathophysiology of cardiovascular disease. Eur Heart J Suppl 2006, 8:A6-A9.
19. Pieske B., Maier L.S., Piacentino V., et al. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation 2002, 106:447-453.
20. Pieske B., Houser S.R. [Na+]i handling in the failing human heart. Cardiovasc Res 2003, 57:874-886.
21. Haigney M.C., Lakatta E.G., Stern M.D., et al. Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading. Circulation 1994, 90:391-399.
22. Van Emous J.G., Nederhoff M.G., Ruigrok T.J., et al. The role of the Na+ channel in the accumulation of intracellular Na+ during myocardial ischemia: consequences for post-ischemic recovery. J Mol Cell Cardiol 1997, 29:85-96.
23. Baetz D., Bernard M., Pinet C., et al. Different pathways for sodium entry in cardiac cells during ischemia and early reperfusion. Mol Cell Biochem 2003, 242:115-120.
24. Lederer W.J., Tsien R.W. Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in Purkinje fibres. J Physiol 1976, 263:73-100.
25. Wasserstrom J.A., Sharma R., O'Toole M.J., et al. Ranolazine antagonizes the effects of increased late sodium current on intracellular calcium cycling in rat isolated intact heart. J Pharmacol Exp Ther 2009, 331:382-391.
26. Pruvot E.J., Katra R.P., Rosenbaum D.S., et al. Role of calcium cycling versus restitution in the mechanism of repolarization alternans. Circ Res 2004, 94:1083-1090.
27. Valdivia C.R., Chu W.W., Pu J., et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 2005, 38:475-483.
28. Antzelevitch C., Shimizu W., Yan G.X., et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999, 10:1124-1152.
29. Honerjager P. Cardioactive substances that prolong the open state of sodium channels. Rev Physiol Biochem Pharmacol 1982, 92:1-74.
30. Shang L.L., Sanyal S., Pfahnl A.E., et al. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol 2008, 294:C372-C379.
31. Ma J.H., Luo A.T., Zhang P.H. Effect of hydrogen peroxide on persistent sodium current in guinea pig ventricular myocytes. Acta Pharmacol Sin 2005, 26:828-834.
32. Matsumura H., Hara A., Hashizume H., et al. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol 1998, 77:31-39.
33. Song Y., Shryock J.C., Wagner S., et al. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 2006, 318:214-222.
34. Ahern G.P., Hsu S.F., Klyachko V.A., et al. Induction of persistent sodium current by exogenous and endogenous nitric oxide. J Biol Chem 2000, 275:28810-28815.
35. Gautier M., Zhang H., Fearon I.M. Peroxynitrite formation mediates LPC-induced augmentation of cardiac late sodium currents. J Mol Cell Cardiol 2008, 44:241-251.
36. Ju Y.K., Saint D.A., Gage P.W. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 1996, 497(Pt 2):337-347.
37. Fearon I.M., Brown S.T. Acute and chronic hypoxic regulation of recombinant hNa(v)1.5 alpha subunits. Biochem Biophys Res Commun 2004, 324:1289-1295.
38. Saint D.A. The role of the persistent Na(+) current during cardiac ischemia and hypoxia. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S96-S103.
39. Ma J.H., Wang X.P., Zhang P.H. Mechanisms on nitric oxide increasing persistent sodium current of ventricular myocytes in guinea pig during normoxia and hypoxia. Acta Pharmacol Sin 2004, 56:603-608.
40. Wu J., Corr P.B. Palmitoylcarnitine increases [Na+]i and initiates transient inward current in adult ventricular myocytes. Am J Physiol 1995, 268:H2405-H2417.
41. Undrovinas A.I., Fleidervish I.A., Makielski J.C. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 1992, 71:1231-1241.
42. Wu Y., Song Y., Belardinelli L., et al. The late INa inhibitor ranolazine attentuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction. J Pharmacol Exp Ther 2009, 330(2):550-557.
43. Kohlhardt M., Fichtner H., Frobe U. Metabolites of the glycolytic pathway modulate the activity of single cardiac Na+ channels. FASEB J 1989, 3:1963-1967.
44. Pinet C., Algalarrondo V., Sablayrolles S., et al. Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes. Mol Pharmacol 2008, 73:1622-1631.
45. Biswas S., DiSilvestre D., Tian Y., et al. Calcium-mediated dual-mode regulation of cardiac sodium channel gating. Circ Res 2009, 104:870-878.
46. Aiba T., Hesketh G.G., Liu T., et al. Na+ channel regulation by Ca2+/calmodulin and Ca2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes. Cardiovasc Res 2010, 85:454-463.
47. Tan H.L., Kupershmidt S., Zhang R., et al. A calcium sensor in the sodium channel modulates cardiac excitability. Nature 2002, 415:442-447.
48. Wagner S., Dybkova N., Rasenack E.C., et al. Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest 2006, 116:3127-3138.
49. Undrovinas A., Maltsev V.A. Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart. Cardiovasc Hematol Agents Med Chem 2008, 6:348-359.
50. Undrovinas A.I., Belardinelli L., Undrovinas N.A., et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S169-S177.
51. Maltsev V.A., Reznikov V., Undrovinas N.A., et al. Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences. Am J Physiol Heart Circ Physiol 2008, 294:H1597-H1608.
52. Undrovinas N.A., Maltsev V.A., Belardinelli L., et al. Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure. J Physiol Sci 2010, 60:245-257.
53. Maltsev V.A., Sabbah H.N., Higgins R.S., et al. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998, 98:2545-2552.
54. Undrovinas A.I., Maltsev V.A., Sabbah H.N. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 1999, 55:494-505.
55. Huang B., El Sherif T., Gidh-Jain M., et al. Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol 2001, 12:218-225.
56. Chauhan V.S., Tuvia S., Buhusi M., et al. Abnormal cardiac Na(+) channel properties and QT heart rate adaptation in neonatal ankyrin(B) knockout mice. Circ Res 2000, 86:441-447.
57. Ueda K., Valdivia C., Medeiros-Domingo A., et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A 2008, 105:9355-9360.
58. Mazzone A., Strege P.R., Tester D.J., et al. A mutation in telethonin alters Nav1.5 function. J Biol Chem 2008, 283:16537-16544.
59. Vatta M., Ackerman M.J., Ye B., et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006, 114:2104-2112.
60. George A.L. Inherited disorders of voltage-gated sodium channels. J Clin Invest 2005, 115:1990-1999.
61. Li C.Z., Wang X.D., Wang H.W., et al. Four types of late Na channel current in isolated ventricular myocytes with reference to their contribution to the lastingness of action potential plateau. Sheng Li Xue Bao 1997, 49:241-248.
62. Maltsev V.A., Undrovinas A.I. A multi-modal composition of the late Na+ current in human ventricular cardiomyocytes. Cardiovasc Res 2006, 69:116-127.
63. Liu Y.M., DeFelice L.J., Mazzanti M. Na channels that remain open throughout the cardiac action potential plateau. Biophys J 1992, 63:654-662.
64. Patlak J.B., Ortiz M. Slow currents through single sodium channels of the adult rat heart. J Gen Physiol 1985, 86:89-104.
65. Zilberter Y., Starmer C.F., Starobin J., et al. Late Na channels in cardiac cells: the physiological role of background Na channels. Biophys J 1994, 67:153-160.
66. Attwell D., Cohen I., Eisner D., et al. The steady state TTX-sensitive (" window" ) sodium current in cardiac Purkinje fibres. Pflugers Arch 1979, 379:137-142.
67. Bean B.P. The molecular machinery of resurgent sodium current revealed. Neuron 2005, 45:185-187.
68. Clancy C.E., Tateyama M., Liu H., et al. Non-equilibrium gating in cardiac Na+ channels: an original mechanism of arrhythmia. Circulation 2003, 107:2233-2237.
69. Zimmer T., Surber R. SCN5A channelopathies-an update on mutations and mechanisms. Prog Biophys Mol Biol 2008, 98:120-136.
70. Ulbricht W. Sodium channel inactivation: molecular determinants and modulation. Physiol Rev 2005, 85:1271-1301.
71. West J.W., Patton D.E., Scheuer T., et al. A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation. Proc Natl Acad Sci U S A 1992, 89:10910-10914.
72. Deschenes I., Trottier E., Chahine M. Implication of the C-terminal region of the alpha-subunit of voltage-gated sodium channels in fast inactivation. J Membr Biol 2001, 183:103-114.
73. Kass R.S. Sodium channel inactivation in heart: a novel role of the carboxy-terminal domain. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S21-S25.
74. Johnson D., Bennett E.S. Isoform-specific effects of the beta2 subunit on voltage-gated sodium channel gating. J Biol Chem 2006, 281:25875-25881.
75. Maltsev V.A., Kyle J.W., Undrovinas A. Late Na+ current produced by human cardiac Na+ channel isoform Nav1.5 is modulated by its beta1 subunit. J Physiol Sci 2009, 59:217-225.
76. Abriel H. Cardiac sodium channel Nav1.5 and interacting proteins: physiology and pathophysiology. J Mol Cell Cardiol 2010, 48:2-11.
77. Ruan Y., Liu N., Priori S.G. Sodium channel mutations and arrhythmias. Nat Rev Cardiol 2009, 6:337-348.
78. Tateyama M., Rivolta I., Clancy C.E., et al. Modulation of cardiac sodium channel gating by protein kinase A can be altered by disease-linked mutation. J Biol Chem 2003, 278:46718-46726.
79. Murray K.T., Hu N.N., Daw J.R., et al. Functional effects of protein kinase C activation on the human cardiac Na+ channel. Circ Res 1997, 80:370-376.
80. Light P.E., Wallace C.H., Dyck J.R. Constitutively active adenosine monophosphate-activated protein kinase regulates voltage-gated sodium channels in ventricular myocytes. Circulation 2003, 107:1962-1965.
81. Ahern C.A., Zhang J.F., Wookalis M.J., et al. Modulation of the cardiac sodium channel NaV1.5 by Fyn, a Src family tyrosine kinase. Circ Res 2005, 96:991-998.
82. Jespersen T., Gavillet B., van Bemmelen M.X., et al. Cardiac sodium channel Na(v)1.5 interacts with and is regulated by the protein tyrosine phosphatase PTPH1. Biochem Biophys Res Commun 2006, 348:1455-1462.
83. Valdivia C.R., Ueda K., Ackerman M.J., et al. GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A. Am J Physiol Heart Circ Physiol 2009, 297:H1446-H1452.
84. Zhang X.Q., Yamada S., Barry W.H. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia. J Cardiovasc Pharmacol 2008, 51(5):443-449.
85. Le Grand B., Vie B., Talmant J.M., et al. Alleviation of contractile dysfunction in ischemic hearts by slowly inactivating Na+ current blockers. Am J Physiol 1995, 269:H533-H540.
86. Saint D.A. The cardiac persistent sodium current: an appealing therapeutic target?. Br J Pharmacol 2008, 153:1133-1142.
87. Letienne R., Bel L., Bessac A.M., et al. Myocardial protection by F 15845, a persistent sodium current blocker, in an ischemia-reperfusion model in the pig. Eur J Pharmacol 2009, 624:16-22.
88. Vacher B., Pignier C., Letienne R., et al. F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models. Br J Pharmacol 2009, 156:214-225.
89. Vie B., Sablayrolles S., Letienne R., et al. 3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5- benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by reduction of the intracellular Na+ overload. J Pharmacol Exp Ther 2009, 330:696-703.
90. Sossalla S., Wagner S., Rasenack E., et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008, 45:32-43.
91. Pogwizd S.M., Schlotthauer K., Li L., et al. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001, 88:1159-1167.
92. Burstein B., Comtois P., Michael G., et al. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 2009, 105:1213-1222.
93. Glukhov A.V., Fedorov V.V., Lou Q., et al. Transmural dispersion of repolarization in failing and nonfailing human ventricle. Circ Res 2010, 106:981-991.
94. Morita N., Sovari A.A., Xie Y., et al. Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress. Am J Physiol Heart Circ Physiol 2009, 297:H1594-H1605.
95. Zaniboni M., Pollard A.E., Yang L., et al. Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. Am J Physiol Heart Circ Physiol 2000, 278:H677-H687.
96. Spitzer K.W., Pollard A.E., Yang L., et al. Cell-to-cell electrical interactions during early and late repolarization. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S8-S14.
97. Sossalla S., Kallmeyer B., Wagner S., et al. Altered Na(+) currents in atrial fibrillation. Effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010, 55:2330-2342.
98. Wu L., Rajamani S., Li H., et al. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart. Am J Physiol Heart Circ Physiol 2009, 297:H1048-H1057.
99. Wu L., Shryock J.C., Song Y., et al. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 2006, 316:718-726.
100. Di Diego J.M., Belardinelli L., Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003, 108:1027-1033.
101. Thomsen M.B., Verduyn S.C., Stengl M., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004, 110:2453-2459.
102. Wu L., Shryock J.C., Song Y., et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004, 310:599-605.
103. Wang W., Robertson C., Dhalla A.K., et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther 2008, 325:875-881.
104. Van Wagoner D.R. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008, 52:306-313.
105. Guo D., Young L., Wu Y., et al. Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: its role in the genesis of atrial arrhythmias. Am J Physiol Heart Circ Physiol 2010, 298:H1375-H1381.
106. Wu J., Cheng L., Lammers W.J., et al. Sinus node dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine. Prog Biophys Mol Biol 2008, 98:198-207.
107. Song Y., Shryock J.C., Belardinelli L. A slowly-inactivating sodium current contributes to spontaneous diastolic depolarization of atrial myocytes. Am J Physiol Heart Circ Physiol 2009, 297:H1254-H1262.
108. Song Y., Shryock J.C., Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008, 294:H2031-H2039.
109. Song Y., Shryock J.C., Wu L., et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004, 44:192-199.
110. Shryock J.C., Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol 2008, 153:1128-1132.
111. Boden W.E. Ranolazine and its anti-ischemic effects: revisiting an old mechanistic paradigm anew?. J Am Coll Cardiol 2010, 56:943-945.
112. Fedida D., Orth P.M., Hesketh J.C., et al. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S71-S78.
113. Sicouri S., Antzelevitch D., Heilmann C., et al. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome. J Cardiovasc Electrophysiol 1997, 8:1280-1290.
114. Pignier C., Rougier J.S., Vie B., et al. Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol 2010, 161:79-91.
115. VerDonck L., Borgers M., Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle. Cardiovasc Res 1993, 27:349-357.
116. Dhalla A.K., Wang W.Q., Dow J., et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2009, 297:H1923-H1929.
117. Gralinski M.R., Chi L., Park J.L., et al. Protective effects of ranolazine on ventricular fibrillation induced by activation of the ATP-dependent potassium channel in the rabbit heart. J Cardiovasc Pharmacol Ther 1996, 1:141-148.
118. Kloner R.A., Dow J.S., Bhandari A. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel. Cardiovasc Ther 2010, [Epub ahead of print].
119. Le Grand B., Pignier C., Letienne R., et al. Na+ currents in cardioprotection: better to be late. J Med Chem 2009, 52:4149-4160.
120. Antzelevitch C., Belardinelli L., Wu L., et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004, 9(Suppl 1):S65-S83.
121. Sicouri S., Glass A., Belardinelli L., et al. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008, 5:1019-1026.
122. Wu Y., Roden D.M., Anderson M.E. Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res 1999, 84:906-912.
123. Katra R.P., Laurita K.R. Cellular mechanism of calcium-mediated triggered activity in the heart. Circ Res 2005, 96:535-542.
124. Curran J., Brown K.H., Santiago D.J., et al. Spontaneous Ca waves in ventricular myocytes from failing hearts depend on Ca(2+)-calmodulin-dependent protein kinase II. J Mol Cell Cardiol 2010, 49:25-32.
125. Maier L.S., Zhang T., Chen L., et al. Transgenic CaMKIIdeltaC overexpression uniquely alters cardiac myocyte Ca2+ handling: reduced SR Ca2+ load and activated SR Ca2+ release. Circ Res 2003, 92:904-911.
126. Maier L.S. Role of CaMKII for signaling and regulation in the heart. Front Biosci 2009, 14:486-496.
127. Fredj S., Lindegger N., Sampson K.J., et al. Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes. Circ Res 2006, 99:1225-1232.
128. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007, 9(Suppl 4):4-15.
129. Flaim S.N., Giles W.R., McCulloch A.D. Contributions of sustained INa and IKv43 to transmural heterogeneity of early repolarization and arrhythmogenesis in canine left ventricular myocytes. Am J Physiol Heart Circ Physiol 2006, 291:H2617-H2629.
130. Restivo M., Caref E.B., Kozhevnikov D.O., et al. Spatial dispersion of repolarization is a key factor in the arrhythmogenicity of long QT syndrome. J Cardiovasc Electrophysiol 2004, 15:323-331.
131. Milberg P., Reinsch N., Wasmer K., et al. Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res 2005, 65:397-404.
132. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004, 110:904-910.
133. Josephson I.R., Sperelakis N. Tetrodotoxin differentially blocks peak and steady-state sodium channel currents in early embryonic chick ventricular myocytes. Pflugers Arch 1989, 414:354-359.
134. Carmeliet E. Slow inactivation of the sodium current in rabbit cardiac Purkinje fibres. Pflugers Arch 1987, 408:18-26.
135. Carmeliet E. Voltage-dependent block by tetrodotoxin of the sodium channel in rabbit cardiac Purkinje fibers. Biophys J 1987, 51:109-114.
136. Hale S.L., Shryock J.C., Belardinelli L., et al. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008, 44:954-967.
137. Belardinelli L., Shryock J.C., Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006, 92(Suppl 4):iv6-iv14.
138. Keating G.M. Ranolazine a review of its use in chronic stable angina pectoris. Drugs 2008, 68(17):2483-2503.
139. Nash D.T., Nash S.D. Ranolazine for chronic stable angina. Lancet 2008, 372:1335-1341.
140. Le Grand B., Pignier C., Letienne R., et al. Sodium late current blockers in ischemia reperfusion: is the bullet magic?. J Med Chem 2008, 51:3856-3866.
141. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001, 103:2004-2013.
142. Okada Y., Ogawa S., Sadanaga T., et al. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol 1996, 27:84-89.
143. Belardinelli L., Antzelevitch C., Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003, 24:619-625.
144. Belardinelli L., Shryock J.C., Wu L., et al. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm 2005, 2:S16-S22.
145. Wu L., Guo D., Li H., et al. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 2008, 5:1726-1734.
146. Wu L., Rajamani S., Shryock J.C., et al. Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res 2008, 77:481-488.
147. Wang J.X., Maruyama K., Murakami M., et al. Antianginal effects of ranolazine in various experimental models of angina. Arzneimittelforschung 1999, 49:193-199.
148. Verscheure Y., Pouget G., De Court, et al. Attenuation by R 56865, a novel cytoprotective drug, of regional myocardial ischemia- and reperfusion-induced electrocardiographic disturbances in anesthetized rabbits. J Cardiovasc Pharmacol 1995, 25:126-133.
149. Janse M.J. Electrophysiology and electrocardiology of acute myocardial ischemia. Can J Cardiol 1986, (Suppl A):46A-52A.
150. Rajamani S., El Bizri N., Shryock J.C., et al. Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm 2009, 6:1625-1631.
151. Rajamani S., Shryock J.C., Belardinelli L. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin) 2008, 2:449-460.
152. Carmeliet E., Tytgat J. Agonistic and antagonistic effect of R56865 on the Na+ channel in cardiac cells. Eur J Pharmacol 1991, 196:53-60.
153. Noble D., Varghese A. Modelling of sodium-overload arrhythmias and their suppression. Can J Cardiol 1998, 14:97-100.
154. Comtois P., Sakabe M., Vigmond E.J., et al. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. Am J Physiol Heart Circ Physiol 2008, 295:H1489-H1504.
155. Hartmann M., Decking U.K., Schrader J. Cardioprotective actions of KC 12291. II. Delaying Na+ overload in ischemia improves cardiac function and energy status in reperfusion. Naunyn Schmiedebergs Arch Pharmacol 1998, 358:554-560.
156. Gralinski M.R., Black S.C., Kilgore K.S., et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 1994, 28:1231-1237.
157. John G.W., Letienne R., Le Grand B., et al. KC 12291: an atypical sodium channel blocker with myocardial antiischemic properties. Cardiovasc Drug Rev 2004, 22:17-26.
158. Fraser H., Belardinelli L., Wang L., et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006, 41:1031-1038.
159. Hale S.L., Kloner R.A. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther 2006, 11:249-255.
160. Belardinelli L., Antzelevitch C., Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent effects on cardiomyocyte function. Eur Heart J 2004, 6(Suppl 1):13-17.
161. Belardinelli L., Shryock J.C., Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 2006, 8(Suppl A):A10-A13.
162. Hasenfuss G., Maier L.S. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 2008, 97:222-226.
163. Dipla K., Mattiello J.A., Margulies K.B., et al. The sarcoplasmic reticulum and the Na+/Ca2+ exchanger both contribute to the Ca2+ transient of failing human ventricular myocytes. Circ Res 1999, 84:435-444.
164. Eigel B.N., Hadley R.W. Antisense inhibition of Na+/Ca2+ exchange during anoxia/reoxygenation in ventricular myocytes. Am J Physiol Heart Circ Physiol 2001, 281:H2184-H2190.
165. Hayashida W., van Eyll C., Rousseau M.F., et al. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994, 8:741-747.
166. Bassand J. Clinical implications of inhibition of the late sodium current: ranolazine. Eur Heart J 2006, 8(Suppl A):A14-A19.
167. Chaitman B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113:2462-2472.
168. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291:309-316.
169. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375-1382.
170. Pepine C.J., Wolff A. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 1999, 84:46-50.
171. Rousseau M., Pouleur H., Cocco G., et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005, 95:311-316.
172. Scirica B.M. Ranolazine in patients with coronary artery disease. Expert Opin Pharmacother 2007, 8(13):2149-2157.
173. Siddiqui A.A.A., Keam S.J. Ranolazine. A review of its use in chronic stable angina pectoris. Drugs 2006, 66(5):693-710.
174. Stone P.H., Gratsiansky N.A., Blokhin A., et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine. J Am Coll Cardiol 2006, 48:566-575.
175. Timmis A.D., Chaitman B.R., Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006, 27:42-48.
176. Wilson S.R., Scirica B.M., Braunwald E., et al. Efficacy of ranolazine in patients with chronic angina. J Am Coll Cardiol 2009, 53:1510-1516.
177. Morrow D.A., Scirica B.M., Prokopczuk E., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation Acute Coronary Syndromes. JAMA 2007, 297:1775-1783.
178. Murdock D., Overton N., Kersten M., et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008, 8(3):175-181.
179. Scirica B.M., Morrow D.A., Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome. Circulation 2007, 116:1647-1652.
180. Murdock D., Kaliebe J., Overton N. Ranolazine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report. Pacing Clin Electrophysiol 2008, 31:765-768.
181. Eid F., Boden W.E. The evolving role of medical therapy for chronic stable angina. Curr Cardiol Rep 2008, 10:263-271.
182. Hwang H., Arcidi J.M., Hale S.L., et al. Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. J Cardiovasc Pharmacol Ther 2009, 14:125-133.
183. Wang P., Fraser H., Lloyd S.G., et al. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007, 321:213-220.
184. Sharikabad M.N., Aronsen J.M., Haugen E., et al. Cardiomyocytes from postinfarction failing rat hearts have improved ischemia tolerance. Am J Physiol Heart Circ Physiol 2009, 296:H787-H795.
185. Tamareille S., Le Grand B., John G.W., et al. Anti-ischemic compound KC 12291 prevents diastolic contracture in isolated atria by blockade of voltage-gated sodium channels. J Cardiovasc Pharmacol 2002, 40:346-355.
186. Kumar K., Nearing B.D., Carvas M., et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009, 20:796-802.
187. Maruyama K., Hara A., Hashizume H., et al. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol 2000, 52:709-715.
188. Lu H.R., De Clerck F. R 56865, a Na+/Ca(2+)-overload inhibitor, protects against aconitine-induced cardiac arrhythmias in vivo. J Cardiovasc Pharmacol 1993, 22:120-125.
189. Sawanobori T., Hirano Y., Hiraoka M. Aconitine-induced delayed afterdepolarization in frog atrium and guinea pig papillary muscles in the presence of low concentrations of Ca2+. Jpn J Physiol 1987, 37:59-79.
190. Sawanobori T., Adaniya H., Hirano Y., et al. Effects of antiarrhythmic agents and Mg2+ on aconitine-induced arrhythmias. Jpn Heart J 1996, 37:709-718.
191. Leyssens A., Carmeliet E. Block of the transient inward current by R56865 in guinea-pig ventricular myocytes. Eur J Pharmacol 1991, 196:43-51.
192. Sheu S.S., Lederer W.J. Lidocaine's negative inotropic and antiarrhythmic actions. Dependence on shortening of action potential duration and reduction of intracellular sodium activity. Circ Res 1985, 57:578-590.
193. Vollmer B., Meuter C., Janssen P.A. R 56865 prevents electrical and mechanical signs of ouabain intoxication in guinea-pig papillary muscle. Eur J Pharmacol 1987, 142:137-140.
194. Rastogi S., Sharov V.G., Mishra S., et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008, 295:H2149-H2155.
195. Sabbah H.N., Chandler M.P., Mishima T., et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002, 8:416-422.
196. Fraser H, Ivey PE, Kato J, et al. Ranolazine reduces ATX-II-induced contracture in rat left atria. The 25th European Section Meeting. International Society for Heart Research. Tromsø, Norway, June 21-25, 2005.
197. Fazekas T., Krassoi I., Lengyel C., et al. Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. Pacing Clin Electrophysiol 1998, 21:147-150.
198. Abrahamsson C., Carlsson L., Duker G. Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarization and early afterdepolarizations in vitro. J Cardiovasc Electrophysiol 1996, 7:1074-1081.
199. Antoons G., Oros A., Beekman J.D., et al. Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol 2010, 55:801-809.
200. Burashnikov A., Di Diego J.M., Zygmunt A.C., et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007, 116:1449-1457.
201. Carvas M., Nascimento B.C., Acar M., et al. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovasc Pharmacol 2010, 55:286-291.
202. Kumar K., Nearing B.D., Bartoli C.R., et al. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol 2008, 19:1073-1079.
203. Burashnikov A., Antzelevitch C. Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs 2009, 14:233-249.
204. Ruan Y., Liu N., Bloise R., et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007, 116:1137-1144.
205. Moss A.J., Zareba W., Schwarz K.Q., et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 2008, 19:1289-1293.
206. Arakawa J., Hara A., Kokita N. Lidocaine attentuates mechanical and metabolic derangements induced by Palmitoyl-L-Carnitine in the isolated perfused rat heart. Pharmacology 1997, 55:259-268.
207. Ravens U., Himmel H.M. Drugs preventing Na+ and Ca2+ overload. Pharmacol Res 1999, 39:167-174.